The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

This study has been completed.

First Received: March 24, 2008 Last Updated: September 16, 2008 History of Changes

Sponsored by:	University of Oklahoma
Information provided by:	University of Oklahoma
ClinicalTrials.gov Identifier:	NCT00644657

Purpose

This study will explore the effect of clopidogrel on coated-platelets in patients who are given an loading dose before diagnostic catheterization or percutaneous coronary intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and therefore more hypercoagulable.

Condition	Intervention
Heart Catheterization	Drug: Clopidogrel

Study Type:	Interventional
Study Design:	Basic Science, Open Label, Single Group Assignment
Official Title:	The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Resource links provided by NLM:

Drug Information available for: Clopidogrel Clopidogrel Bisulfate

U.S. FDA Resources

Further study details as provided by University of Oklahoma:

Primary Outcome Measures:

Change in the percentage of coated platelets [ Time Frame: Within 24 hours ] [ Designated as safety issue: No ]

Estimated Enrollment:	32
Study Start Date:	March 2007
Study Completion Date:	September 2008
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Clopidogrel 300 mg loading dose

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients given clopidogrel loading dose before scheduled catheterization or percutaneous intervention

Exclusion Criteria:

Acute coronary syndrome
Unable to tolerate clopidogrel

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00644657

Locations

United States, Oklahoma
VA Medical Center, 1F187
Oklahoma City, Oklahoma, United States, 73104-5076

Sponsors and Collaborators

University of Oklahoma

Investigators

Principal Investigator:

Eliot Schechter, MD

University of Oklahoma

More Information

No publications provided

Responsible Party:	University of Oklahoma Health Sciences Center ( Dr. Eliot Schechter )
Study ID Numbers:	13291
Study First Received:	March 24, 2008
Last Updated:	September 16, 2008
ClinicalTrials.gov Identifier:	NCT00644657 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Oklahoma:

Platelets, platelet aggregation inhibitors

Study placed in the following topic categories:

Clopidogrel
Platelet Aggregation Inhibitors

Additional relevant MeSH terms:

Therapeutic Uses
Clopidogrel
Hematologic Agents
Platelet Aggregation Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 10, 2009